STAT+: Josh Bilenker’s last biotech sold for $8 billion. His next one is cloaked in mystery but loaded with money
Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No surprise, then, that his next effort has already raised at least $473 million in funding from private investors even before telling the public what, exactly, it is working on.
Treeline Biosciences, the new venture by Bilenker and Jeffrey Engelman, formerly Novartis’s top cancer researcher, has hired more than 130 people across three research sites in little more than a year, according to a company blog post, regulatory filings, and STAT reporting.
